Clinical uses of mifepristone: An update for women's health practitioners

Journal of Midwifery and Women's Health

Volumn 47, Issue 6, 2002, Pages 451-460

  Beal, Margaret W ^a   Simmonds, Kathy ^b  

^a YALE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; MIFEPRISTONE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRIMETHOBENZAMIDE;

ABDOMINAL CRAMP; BLEEDING; BREAST CANCER; CHILL; CLINICAL PROTOCOL; CONTRACEPTION; CUSHING DISEASE; DOSE CALCULATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG USE; FEMALE; FEVER; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEADACHE; HEALTH CARE; HEALTH PRACTITIONER; HUMAN; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; MATERNAL CARE; PATIENT COUNSELING; RECEPTOR BINDING; REVIEW; STOMACH ULCER; THERAPEUTIC ABORTION; TREATMENT OUTCOME; UNITED STATES; VERTIGO;

EID: 0037069535     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9523(02)00331-8     Document Type: Article

References (66)

1. Kaiser Family Foundation. National Survey of women's health care providers on reproductive health: medical abortion results. Menlo Park (CA): Kaiser Family Foundation, 2001.
2. Baulieu EE. The abortion pill: RU-486-a women's choice. New York: Simon and Schuster; 1990.
3. Creinin MD. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol 2000;183:S3-S9.
4. Kovacs L, Sas M, Resch BA, Ugocasai G, Swahn ML, Bygdeman M, et al. Termination of very early pregnancy by RU 486-an antiprogestational compound. Contraception 1984;29:399-410.
5. Swahn ML, Ugocsai G, Bygdeman M, Kovacs L, Belsey EM, Van Look PF. Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy. Hum Reprod 1989;4:21-8.
6. Grimes DA. Medical abortion: public health and private lives. Am J Obstet Gynecol 2000;183:S1-S2.
7. Vastag B. Effect of mifepristone approval on research remains to be seen. J Natl Cancer Inst 2000;92:1970-1.
8. Zitner A. Whatever happened to the saga of RU-486? Boston Globe Magazine. 1997; November 18-26.
9. Ulmann A. The development of mifepristone: a pharmaceutical drama in three acts. J Am Med Wom Assoc 2000;55:117-20.
10. Cullen M. Letter to health care practitioners: important drug warning concerning unapproved use of intravaginal or oral misoprostol in pregnant women for induction of labor or abortion. Skokie (IL): Searle; August 23, 2000.
11. Zinberg S. ACOG news release: ACOG writes FDA on safety of misoprostol. Available from: URL: http://www.acog.com/from_home/publications/press_releases/nr10-27-00.htm.
12. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001;344(1):38-47.
13. Hale RW, Zinberg S. Use of misoprostol in pregnancy. N Engl J Med 2001;344(1):59-60.
14. Federal Drug Administration. Cytotec (misoprostol) tablets label. Available from: URL: www.nih.gov/cder/foi/label/2002/19268slr037.pdf.
15. Crenin MD, Aubeny E. Medical abortion in early pregnancy. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, editors. A clinician's guide to medical and surgical abortion. Philadelphia (PA): Churchill Livingstone; 1999:91-106.
16. Miller J. Endocrine and metabolic disorders. In: Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW, editors. Melmon and Morrelli's clinical pharmacology. New York: McGraw-Hill; 2000.
17. Baird DT. Mode of action of medical methods of abortion. J Am Med Wom Assoc 2000;55:121-6.
18. Heikinheimo O. Clinical pharmocokinetics of mifepristone. Clin Pharmacokinet 1997;33:7-17.
19. Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroid 2000;65:807-15.
20. Blanchard K, Winikoff B, Coyaji K, Nguyen TN. Misoprostol alone-a new method of medical abortion? J Am Med Wom Assoc 2000;55(3S):89-90.
21. Pollack AE, Pine RN. Opening a door to safe abortion: international perpectives on medical abortifacient use. J Am Med Wom Assoc 2000; 55(3S):186-8.
22. Rosing MA, Archbald CD. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban U.S. population. J Am Med Wom Assoc 2000;55(3S):183-185.
23. Gonzalez CH, Marques-Dias MJ, Kim CA, Sugayama SMM, Paz JAD, Huson SM, et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624-7.
24. Stewart FH, Wells ES, Flinn SK, Weitz TA. Early medical abortion: issues for practice. San Francisco (CA): UCSF Center for Reproductive Health Research and Policy; 2001. Report No.: FHS-2001-001.
25. Danco Laboratories L. Mifeprex™ (Mifepristone) tablets, 200 mg prescriber's agreement/patient's agreement. Available from: URL: http://earlyoptionspill.com. Patient's agreement:/mayreement/php3. Prescriber's agreement:/hcpw.php3.
26. From the Federal Drug Administration. Mifeprex TM (mifepristone) tablets, label 2000 mg. for oral administration only. Available from: URL:http//www.fda.gov/cder/foi/label/2000/20687lbl.htm.
27. National Abortion Federation. Early options: a provider's guide to medical abortion. Washington (DC): National Abortion Federation, 2001.
28. Aubeny E, Peyon R, Turpin CL. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil Menopaus Stud 1995;40:85-91.
29. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-7.
30. Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik F, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993;328:1509-13.
31. Ngoc N, Winikoff B, Clark S. Safety, efficacy, and acceptability of mifepristone-misoprostol abortion in Vietnam. Int Fam Plan Perspect 1999;25:10-33.
32. Ashok PW, Penney GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998;13:2962-5.
33. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BMJ 2000;307:532-7.
34. Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999;59:1-6.
35. McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 1993;8:1502-5.
36. el-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983-7.
37. Kahn JG, Becker BJ, MacIsaa L, Amory JK, Neuhaus J, Olkin I, et al. The efficacy of medical abortion: a meta-analysis. Contraception 2000; 61:29-40.
38. Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. [see comments]. J Fam Pract 1997;44:353-60.
39. Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. J Am Med Wom Assoc 2000;55(3S):169-72.
40. Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadaius LS, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. J Am Med Assoc 2000;284:1948-53. [erratum appears in J Am Med Assoc 2000 Nov 22-29;284:2597].
41. Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol 2000;1813(2):S65-75.
42. Ellertson C, Simonds W, Winikoff B, Springer K, Bagchi D. Providing mifepristone-misoprostol medical abortion: the view from the clinic. J Am Med Wom Assoc 1999;54(2):91-6.
43. Danco Laboratories L. Mifepristone [package insert]. In: Danco Laboratories LLC, 2000. Available from: URL: http://www.earlyoptions.com.
44. Jang GR, Benet LZ. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharmaceut 1997;25:647-72.
45. Kekkonen R, Keikinheimo O, Mandelin E, Lahteenmaki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 1996;54: 299-34.
46. Wing Da, Fassett MJ, Mishell DR. Mifepristone for preinduction cervical ripening beyond 41 weeks' gestation: a randomized controlled trial. Obstet Gynecol 2000;96(4):543-8.
47. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-6.
48. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N. RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000;74:1014-9.
49. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995;64:187-90.
50. Heikinheimo O, Ranta S, Grunberg S, Spitz IM. Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to longterm mifepristone administration. Steroid 2000;65:831-6.
51. Klijin JG, Setrono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroid 2000;65:825-30.
52. Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Cancer 2001;92:469-73.
53. Kacinski BM, Flick MB, Sapi E. RU-486 can abolish glucocorticoid-induced increases in CSF-1 receptor expression in primary human breast carcinoma specimens. J Soc Gynecol Invest 2001;8:114-6.
54. Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen an apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998;51:149-68.
55. Chu JW, Matthias DR, Belanoff J, Schatzberg A, Hoffman AR, Feldmen D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU-486). J Clin Endocrinol Metab 2001;86: 3586-73.
56. Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 2001;54:399-404.
57. Institute of Medicine. Clinical applications of mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Washington (DC): National Academy Press; 1993.
58. Sridhar S, Ali AA, Liang Y, El Etreby MF, Lewis RW, Kumar MV. Differential expression of members of the tumor necrosis factor alpharelated apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res 2001;61:7179-83.
59. Henshaw SK. Abortion incidence and services in the United States, 1995-1996. Fam Plann Perspect 1998;30:263-70.
60. Kruse B. Advanced practice clinicians and medical abortion: increasing access to care. J Am Med Wom Assoc 2000;55(3S):167-8.
61. McKee K, Adams E. Nurse midwives' attitudes toward abortion performance and related procedures. J Nurse Midwifery 1994;39:300-11. [Erratum appears in J Nurse Midwifery 1994 Nov-Dec;39(6):x.]
62. Harvey SM, Beckman JL, Satre SJ. Listening to and learning from health care providers about methotrexate-induced abortions. Los Angeles: Pacific Institute for Women's Health; 1998.
63. National Abortion Federation. Who will provide abortions? Ensuring the availability of qualified practitioners. Washington (DC): National Abortion Federation; 1991.
64. National Abortion Federation. The role of physician's assistants, nurse practitioners and nurse-midwives in providing abortions: strategies for expanding abortion access. Washington (DC): National Abortion Federation; 1991.
65. Tarrant E. Nurse-midwives as abortion providers: current clinical practice, facilitating factors, and barriers [unpublished Master's thesis]. New Haven (CT): Yale University; 1998.
66. Summers L. The genesis of the ACNM statement on abortion. J Nurse Midwifery 1992;37:168-74.